BioKDE

Clinical Trial
Meta-Analysis
Randomized Controlled Trial
Review
Systematic Review

1 year

5 year

10 year

Start Date:

End Date:

385,360 results (0.031 seconds)

RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion.
Yanyan Zhang, Shuyi Zhu, +8 authors, Yong Xu.
J Exp Clin Cancer Res. 2022 Feb 17; 41(1):66. PMID: 35177112 Free PMC article

Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.
Mayassa J Bou-Dargham, Linlin Sha, Qing-Xiang Amy Sang, Jinfeng Zhang.
BMC Cancer. 2020 Jun 18; 20(1):572. PMID: 32552802 Free PMC article

Macrophages in prostate cancer: dual roles in tumor progression and immune evasion.
Ruihong Liu, Jianxin Lu, +6 authors, Jingling Lai.
J Transl Med. 2025 Jun 02; 23(1):615. PMID: 40457341 Free PMC article
Review.

Overcoming immune evasion in advanced prostate cancer.
Andrea Alimonti.
Clin Adv Hematol Oncol. 2023 Nov 10; 21(10):533-535. PMID: 37948589

PCBP2 promotes immune evasion via cGAS-STING pathway in biochemical recurrence of prostate cancer.
Zeng Zhou, Tiewen Li, +6 authors, Yuan Ruan.
APL Bioeng. 2025 Mar 05; 9(1):016112. PMID: 40051782 Free PMC article

Prostate cancer cell-derived exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8+ T cell.
Fan Xu, Xiumei Wang, +11 authors, Yong Xu.
Cell Rep. 2023 Nov 14; 42(11):113424. PMID: 37963015
Highly Cited.

Immunotherapy and immune evasion in prostate cancer.
Archana Thakur, Ulka Vaishampayan, Lawrence G Lum.
Cancers (Basel). 2013 May 24; 5(2):569-90. PMID: 24216992 Free PMC article

Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer.
David R Wise, Jeffrey A Schneider, +26 authors, International SU2C/PCF Prostate Cancer Dream Team.
JCO Precis Oncol. 2020 Sep 29; 4:. PMID: 33015525 Free PMC article

Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancer.
Ida Deichaite, Timothy J Sears, +8 authors, Hannah Carter.
J Transl Med. 2022 Nov 12; 20(1):527. PMID: 36371231 Free PMC article

Flightless I Homolog Reverses Enzalutamide Resistance through PD-L1-Mediated Immune Evasion in Prostate Cancer.
Hailong Ruan, Lin Bao, Zhen Tao, Ke Chen.
Cancer Immunol Res. 2021 May 19; 9(7):838-852. PMID: 34011528

T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.
Yael S Barach, Jun Sik Lee, Xingxing Zang.
Trends Mol Med. 2010 Oct 26; 17(1):47-55. PMID: 20971039 Free PMC article
Review.

Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer.
Sandra Santasusagna, Shijia Zhu, +22 authors, Josep Domingo-Domenech.
Cancer Discov. 2023 Sep 07; 13(12):2584-2609. PMID: 37676710 Free PMC article

Epithelial-Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 Expression.
Kimberley Kolijn, Esther I Verhoef, +4 authors, Geert J L H van Leenders.
Cancer Res. 2018 Jun 19; 78(16):4671-4679. PMID: 29921693

LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1.
Qi-Hua Chen, Bo Li, +3 authors, Ya-Ling Tu.
Cancer Cell Int. 2020 Aug 15; 20:394. PMID: 32821247 Free PMC article

CHD1 dysregulation in cancer: bridging chromatin instability, therapy resistance, and immune evasion.
K S Praveen Kumar, M N Jyothi, Akila Prashant.
Mol Biol Rep. 2025 Apr 25; 52(1):426. PMID: 40278910
Review.

Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms.
Jinhui Guo, Jie Zhao, +2 authors, Dongsheng Huang.
Front Immunol. 2022 Jul 20; 13:918314. PMID: 35935969 Free PMC article
Highly Cited. Review.

DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers.
Jose Mario Bello Pineda, Robert K Bradley.
Elife. 2024 Jun 03; 12:. PMID: 38829686 Free PMC article

Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?
Yishan Liu, Ljiljana Vlatkovic, +5 authors, Karol Axcrona.
Int J Urol. 2012 Apr 04; 19(8):749-56. PMID: 22487487

Pan-cancer genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome.
T Vidotto, C M Melo, +3 authors, J A Squire.
Sci Rep. 2023 Mar 28; 13(1):5049. PMID: 36977733 Free PMC article
Highly Cited.

DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers.
Jose Mario Bello Pineda, Robert K Bradley.
bioRxiv. 2023 Dec 29; :. PMID: 37502871 Free PMC article

Next